Recursion Pharmaceuticals, Inc.: financial statements

RXRXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.80

November 17, 2026Market cap $1.7B

What Ploutos Investor adds for Recursion Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 24% since Nov 2, 2026, when the 10-Q these figures come from was filed ($3.83 then, $2.91 on Nov 16, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+29.4% a year over 2 years

Line202320242025Average a year
Revenue $45M$59M$75M+29.4%
Cost of revenue $43M$45M$71M+29.1%
Gross profit $2.0M$14M$3.7M+36.9%
Operating income -$350M-$479M-$648M
Net income -$328M-$464M-$645M
Earnings per share -$1.58-$1.69-$1.44
Earnings per share, basic -$1.58-$1.69-$1.44
Margins
Gross margin 4.5%23.1%5.0%
Operating margin -785.3%-814.1%-867.9%
Net margin -736.0%-788.0%-863.4%

Financial statements

RXRX's revenue, profits and cash flows from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: License And Service $44M, Grant $699.0K
  • 2024: License And Service $58M, Grant $351.0K
  • 2025: License And Service $74M, Grant $425.0K
Product202320242025Share 2025
License And Service$44M$58M$74M99%
Grant$699.0K$351.0K$425.0K0.6%

By segment

RXRX's revenue by product line from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 5 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$78M Leases0.2% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$59M

Finance leases

$18M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Goodwill by segment

Dec 31, 2025

Total goodwill

$162M

The company does not state its goodwill by segment, at December 31, 2025. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.2%

-20.8 pts

The company paid 0.2% in tax on its profit, 20.8 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance · United States

-19.8 pts

Difference the filing does not itemize

-1.0 pts

Effective rate

0.2%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

The full analysis

What do Recursion Pharmaceuticals's filings show?

These are Recursion Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RXRX's financials

Didn't find what you were looking for?

Ask us
How much revenue did RXRX have in 2025?

Recursion Pharmaceuticals had revenue of $75M and net income of -$645M in fiscal 2025, a net margin of -863.4%.

How much debt does RXRX have?

On December 31, 2025 Recursion Pharmaceuticals had total assets of $1.5B, debt of $19M and shareholders' equity of $1.1B.

How much free cash flow does RXRX have?

In fiscal 2025 Recursion Pharmaceuticals had cash from operations of -$372M and spent $6.5M on capital expenditure, leaving -$378M of free cash flow.

Where are the figures from?

From Recursion Pharmaceuticals, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.